ERBB2 and gastric cancer: In the recently published DESTINY-Gastric04 Phase 3 study comparing T-DXd with the standard second-line therapy ramucirumab plus paclitaxel in patients with HER2-positive gastric cancer who failed first-line therapy, the T-DXd group significantly improved mOS (14.7 months vs. 11.4 months; HR = 0.70, p = 0.0044) and progression-free survival (PFS) (6.7 months vs. 5.6 months) in the T-DXd group, demonstrating significant improvement.